Regeneron's macular degeneration drug Eylea is a great success, said Schleifer. The product launched in early 2012 and Schleifer noted that analysts first thought the company would sell $100 million worth of the drug. Later the estimates were raised to a few hundred million dollars, then $500 million. Regeneron is now expected to sell $750 million of Eylea this year and the company only has 14% market share.

Schleifer said that unlike Eylea's chief rival, his company's drug only needs to be given half as often. Since macular degeneration drugs must be given as a direct injection in the eye, it's easy to see why patients prefer Eylea over the competition.

Cramer said the story remains strong at Regeneron, and even after the company's huge move higher "it's not done yet."

Riding the Bull

"Always keep an eye out for the next bull market," Cramer told viewers. The theme park business is one such opportunity.

Cramer said the first clue theme parks might be a good bet came from Walt Disney ( DIS), which reported operating income up at its theme parks by 20%. Next, it was Comcast ( CMCSA), which owns the Universal chain of parks. There too, growth was strong.

This theme park bull market came full circle when pure-plays Cedar Fair ( FUN) and Six Flags ( SIX) reported strong results as well. Cramer said he's a fan of both Six Flags, which operates 19 parks across the U.S., and Cedar Fair, which now totals 11 parks.

Shares of Cedar Fair are up 98%, including dividends, since Cramer featured the company in 2011 and it still sports a 5% dividend yield. When the company last reported, it surprised Wall Street with a 25 cent-a-share earnings beat and stayed true to its promise of raising its dividend.

Six Flags is also on fire, said Cramer, as that company saw 12% earnings growth. Six Flags sports a 4.2% dividend.

Cramer said both companies are pure plays on the theme park business and are 100% domestic with no exposure to Europe. Both companies are investing in new rides and attractions, which are sure to cheap consumers coming back for more with lower gas prices.

If you liked this article you might like

Stalking Regeneron for Key Low and Reversal

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog